CLINICAL TRIALS PROFILE FOR TOBRADEX ST
✉ Email this page to a colleague
505(b)(2) Clinical Trials for TOBRADEX ST
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Formulation | NCT00404937 ↗ | Tobradex BID Compared to TOBRADEX and TOBREX/Vehicle | Withdrawn | Alcon Research | Phase 3 | 2006-12-01 | The purpose of this study is to compare the new formulation of Tobradex to the current approved formulation |
| OTC | NCT01560962 ↗ | Efficacy of Over the Counter (OTC) Povidone-Ioldine 5% for Treatment of Acute or Chronic Blepharitis | Terminated | Southern California Institute for Research and Education | N/A | 2012-01-01 | Objective: To determine the preliminary outcome of external over the counter (OTC) povidone iodine (PI) application in the management of chronic and acute blepharitis vs. currently clinically accepted medical regimen, i.e. eyelid hygiene, antibiotic drops, or antibiotic/steroid ointments. Methodology: One hundred adult patients with chronic and acute blepharitis will be enrolled and randomized into four groups. In group one, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI twice daily for 10 days and the other eye with no intervention. In group two, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI and the other eye will receive warm soaked eyelid wash. In group three, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI and the other eye will receive 1 drop of azithromycin ophthalmic solution twice daily for 10 days. In group four, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI and the other eye will receive tobradex ointment applied to the lid margin. Subjective variables assessed included itchiness, foreign body sensation and eyelid edema (grade 0-4). Objective variables assessed included lid margin redness, meibomian gland plugging and presence/absence of collarets (grade 0-4). Cultures of lid margin at the initiation and at the cessation of treatment were obtained. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for TOBRADEX ST
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00083551 ↗ | UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy | Completed | Celgene Corporation | Phase 3 | 1998-08-01 | This study has been designed to evaluate whether "anti-angiogenesis" therapy with thalidomide and whether additional chemotherapy after transplant will be beneficial. Another objective is to find out what kinds of side effects occur with this combination of treatment and how often they occur. |
| NCT00083551 ↗ | UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy | Completed | University of Arkansas | Phase 3 | 1998-08-01 | This study has been designed to evaluate whether "anti-angiogenesis" therapy with thalidomide and whether additional chemotherapy after transplant will be beneficial. Another objective is to find out what kinds of side effects occur with this combination of treatment and how often they occur. |
| NCT00362895 ↗ | A Bioequivalence Study of Tobradex AF | Completed | Alcon Research | Phase 3 | 2006-04-01 | The purpose of the study is to determine the amount of study medication that moves from the front of the eye into the fluid at the front of the inside of the eye. |
| NCT00404937 ↗ | Tobradex BID Compared to TOBRADEX and TOBREX/Vehicle | Withdrawn | Alcon Research | Phase 3 | 2006-12-01 | The purpose of this study is to compare the new formulation of Tobradex to the current approved formulation |
| NCT00447577 ↗ | Zylet vs TobraDex in Blepharokeratoconjunctivitis | Completed | Bausch & Lomb Incorporated | Phase 4 | 2007-01-01 | The objective of this study is to evaluate the safety and efficacy of Zylet vs. Tobradex in the treatment of ocular inflammation associated with blepharokeratoconjunctivitis |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TOBRADEX ST
Condition Name
Clinical Trial Locations for TOBRADEX ST
Trials by Country
Clinical Trial Progress for TOBRADEX ST
Clinical Trial Phase
Clinical Trial Sponsors for TOBRADEX ST
Sponsor Name
